ImmunoGen, Inc. Announces Webcast of Presentation and Q&A at the 34th Annual J. P. Morgan Healthcare Conference
January 04 2016 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that
develops novel anticancer therapeutics using its antibody-drug
conjugate (ADC) technology, today announced that Daniel Junius,
President and CEO, will present at the upcoming 34th Annual J. P.
Morgan Healthcare Conference in San Francisco. The presentation is
scheduled for 3:00 pm PT (6:00 pm ET) on January 12, 2016.
Following the presentation, Mr. Junius will be joined by other
members of ImmunoGen’s management team for a question-and-answer
session at 3:30pm PT (6:30 pm ET).
A webcast of the presentation and question-and-answer sessions
will be accessible live through the "Investors" section of the
Company's website, www.immunogen.com; a replay will be
available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted anticancer therapeutics using its proprietary ADC
technology. The Company's lead product candidate, mirvetuximab
soravtansine, is a potential treatment for folate receptor
α-positive ovarian cancer and other solid tumors. A number of major
healthcare companies have licensed limited rights to use
ImmunoGen's ADC technology to develop anticancer therapies; it is
used in Roche's marketed product, Kadcyla®. More information about
the Company can be found at www.immunogen.com.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160104005110/en/
ImmunoGen, Inc.Carol Hausner, 781-895-0600info@immunogen.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024